Susquehanna International Group
RAPP

Susquehanna International Group’s Rapport Therapeutics RAPP Stock Holding History

Susquehanna International Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$242K Sell
5,800
-4,700
-45% -$173K ﹤0.01% 11544
2026
Q1 		$329K Buy
+10,500
New +$295K ﹤0.01% 10674
2025
Q4 		– Sell
-36,000
Closed -$1.07M – 13875
2025
Q3 		$1.07M Buy
+36,000
New +$642K ﹤0.01% 7205

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Susquehanna International Group's RAPP Position: Q2 2026 in Review

Susquehanna International Group reduced its Rapport Therapeutics (RAPP) stake by 47% in Q2 2026, selling an estimated $273K and leaving 8,255 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #10753.

Susquehanna International Group first reported a position in RAPP in Q1 2025 and has held it in 6 quarters since. The position peaked at $628K in Q3 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Susquehanna International Group held 8,255 shares of Rapport Therapeutics worth $344K as of Q2 2026.
  • Susquehanna International Group sold 7,417 Rapport Therapeutics shares in Q2 2026, an estimated $273K.
  • Rapport Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #10753 holding.
  • Susquehanna International Group first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Susquehanna International Group's Rapport Therapeutics position peaked at $628K in Q3 2025.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.